Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):670-675.
doi: 10.21037/tcr-24-1936. Epub 2025 Feb 26.

Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses

Sean C Dougherty  1 , Ryan D Gentzler  1
Affiliations
Editorial

Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses

Sean C Dougherty et al. Transl Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); osimertinib mesylate; tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1936/coif). R.D.G. reports the following conflicts of interest for the prior 3 years: research funding to institution from Pfizer, Tempus, Nalo Therapeutics, Puma, Mirati, Bristol Myers Squibb, Dizal, Chugai, Amgen, AstraZeneca, Janssen, Daiichi Sankyo, Jounce Therapeutics, Takeda, Merck, Alliance Foundation, ECOG/ACRIN, NCI, Big Ten Research Consortium, Hoosier Cancer Research Network, and SWOG; Honoraria from Bio Ascend, Academy for Continued Healthcare Learning, Curio, OncLive, Aptitude Health, MedStar Health, Clinical Care Options, Society for Immunotherapy of Cancer (SITC) and American Society of Clinical Oncology; Travel support to meetings from Dava Oncology, Tempus, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC); Consulting fees from Amgen, Genentech, AstraZeneca, Regeneron, Merus, Takeda, Gilead, Janssen; and Leadership roles with Hoosier Cancer Research Network, ASCO, Journal of Clinical Oncology, NCI Investigational Drug Steering Committee, and IASLC Conference Planning Committees. The other author has no conflicts of interest to declare.

Comment on

References

    1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. 10.1093/jnci/dji055 - DOI - PubMed
    1. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985-93. 10.18632/oncotarget.12587 - DOI - PMC - PubMed
    1. Graham RP, Treece AL, Lindeman NI, et al. Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med 2018;142:163-7. 10.5858/arpa.2016-0579-CP - DOI - PubMed
    1. John T, Taylor A, Wang H, et al. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol 2022;76:102080. 10.1016/j.canep.2021.102080 - DOI - PubMed
    1. Amelia T, Kartasasmita RE, Ohwada T, et al. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules 2022;27:819. 10.3390/molecules27030819 - DOI - PMC - PubMed

LinkOut - more resources